DUXAP9 and non-small cell lung carcinoma: To further validate this result, we will collect wild type EGFR specimens from patients with NSCLC to compare the expression of DUXAP9‐206 with normal patient specimens, verify their relationship with relevant signaling pathways and analyse the correlation with survival and prognosis of patients.